Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Kelly Martin takes over at Malin in post-acquisition phase reshuffle

Former Elan CEO Kelly Martin is back at the helm of a business. The controversial dealmaker has taken over as CEO of Malin, the life science investment fund he helped to set up and guide to a €330 million ($380 million) IPO earlier this year.

AstraZeneca lures Sean Bohen from Genentech to fill top R&D post

AstraZeneca has filled the vacancy at the head of its R&D organization. Sean Bohen is set to take up the post next month after being persuaded to swap a position at the heart of early-stage R&D at Genentech for a chance to guide AstraZeneca's late-phase hopefuls toward approval.

Troubled Lundbeck targets 1,000 layoffs in HQ, commercial revamp

Lundbeck is going on a cost-cutting binge. Amid falling sales--and a few months after a new CEO took the helm--the Danish drugmaker says it will cut loose 1,000 employees as part of a plan to save 3 billion kronor, or about $445 million, by 2017.

Art Krieg leads Checkmate as it comes out of stealth mode with $20M

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Merck tallies 36,000 job cuts in 5 years of restructuring

The good news for Merck & Co.'s far-flung workforce: The job cuts hanging over your heads for the past five years are almost finished. The not-so-good news: Several thousand payroll reductions are yet to come.

At Epizyme, CEO Gould steps aside and Bazemore takes the reins

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

GSK rehires former China government affairs director Shi

Reuters reported that GlaxoSmithKline has rehired former China government affairs director Vivian Shi, who was at one point investigated internally by the company as a possible source of leaks into a bribery probe.

Flailing Vivus halves hard-hit Qsymia sales force as revenue lags

Struggling Vivus is short on cash, and it's got a pricey cardiovascular outcomes trial looming in its future. Its fix? Pare down costs once again--or, in the words of RBC Capital Markets analyst Simos Simeonidis, "amputate a limb so that the patient may live."

GSK hiring 130 at inhaler facility, even as CRO axes up to 200 GSK alum

GlaxoSmithKline, which has been laying off hundreds of employees in the face of falling Advair sales, is adding up to 140 employees at a facility in North Carolina. But it is a bittersweet turn of events since as many as 200 former GSK workers in the area who moved to jobs with CRO Parexel are getting their pink slips.

125 ex-GSK R&D staffers in RTP face the ax--again

Eight months after the ax dropped late last year, 125 former GlaxoSmithKline staffers in Research Triangle Park found their jobs back on the chopping block Thursday as their new employer at Parexel included them in a lineup of new layoffs.